Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial

Lee MJ., Cherrill L-R., Zacharopoulou P., Collins S., Fumagalli M., Falaschetti E., Altaf M., Tipoe T., Godakandaarachi P., Fox J., Uriel A., Clarke A., Loes SK-D., Pett S., Boffito M., Whitlock G., Søgaard OS., Ring K., Mangawa I., Gohil J., Elliott T., Nielsen H., Gunst JD., Orkin C., Sutherland R., Hamzah L., Cicconi P., Taylor GP., Ujetz J., Jahan I., Brown H., Robinson N., Fletcher S., Box H., Seaton KE., Tomaras GD., Ackerman ME., Weiner JA., Kaczynska A., Bittar C., Horowitz J., Nussenzweig MC., Caskey M., Frater J., Fidler S.